- Recommendation ID
- DG16/2
- Question
- NICE recommends that robust evidence be generated to show the clinical effectiveness of pharmacokinetic dose adjustment of continuous infusion 5-FU in people with colorectal cancer.
- Any explanatory notes
(if applicable) - Where possible, studies should consider the differential impact that pharmacokinetic dose adjustment may have on people with DPD (dihydropyrimidine dehydrogenase) deficiency, people with impaired renal or liver function, people whose body surface area is outside the standard range for dosing 5-FU and people with a less favourable performance status. Future studies might also consider the impact of DPD testing in conjunction with pharmacokinetic dose adjustment.
Source guidance details
- Comes from guidance
- Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment
- Number
- DG16
- Date issued
- December 2014
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 07/01/2015 |